Cogent Biosciences says mutant-selective JAK2 V617F inhibitor CGT1145 on track for IND in 2026

Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

0.00
  • Cogent Biosciences presented preclinical data at the 2026 European Hematology Association Congress on its mutant-selective JAK2 V617F inhibitor CGT1145.
  • The study supported potential best-in-class positioning, pointing to stronger mutation targeting with fewer off-target blood-related effects than existing JAK inhibitors.
  • The program is being advanced toward an IND filing in 2026, setting up first-in-human clinical testing if regulators clear the application.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120801PRIMZONEFULLFEED9745918) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.